CoChat

Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics

Gómez-Virgilio, Laura, Velazquez-Paniagua, Mireya, Cuazozon-Ferrer, Lucero, Silva-Lucero, Maria-del-Carmen, Gutierrez-Malacara, Andres-Ivan, Padilla-Mendoza, Juan-Ramón, Borbolla-Vázquez, Jessica, Díaz-Hernández, Job-Alí, Jiménez-Orozco, Fausto-Alejandro, Cardenas-Aguayo, Maria-del-Carmen · 2024 · Diagnostics
Cited by 18

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body. It discusses the following aspects of the disease. Genetics: VHL disease is caused by mutations in the VHL tumor suppressor gene located on chromosome 3. These mutations can be inherited or occur spontaneously. This article details the different types of mutations and their associated clinical features. Pathophysiology: The underlying cause of VHL disease is the loss of function of the VHL protein (pVHL). This protein normally regulates hypoxia-inducible factors (HIFs), which are involved in cell growth and survival. When pVHL is dysfunctional, HIF levels become elevated, leading to uncontrolled cell growth and tumor formation. Clinical Manifestations: VHL disease can affect various organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands. Symptoms depend on the location and size of the tumors. Diagnosis: Diagnosis of VHL disease involves a combination of clinical criteria, imaging studies, and genetic testing. Treatment: Treatment options for VHL disease depend on the type and location of the tumors. Surgery is the mainstay of treatment, but other options like radiation therapy may also be used. Challenges: This article highlights the challenges in VHL disease management, including the lack of effective therapies for some tumor types and the need for better methods to monitor disease progression. In conclusion, we emphasize the importance of ongoing research to develop new and improved treatments for VHL disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics14171909

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 171

  1. Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 · DOI · Paper page
  2. Hong, B., Ma, K., Zhou, J., Zhang, J., Wang, J., Liu, S., Zhang, Z., Cai, L., Zhang, N., and Gong, K. (2019). Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort with Von Hippel-Lindau Disease. Front. Genet., 10. · doi:10.3389/fgene.2019.00867
  3. Lonser, 2003, von Hippel-Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4 · DOI · Paper page
  4. McMahon, 2016, Von Hippel-Lindau Disease, J. Pediatr. Genet., 5, 116, 10.1055/s-0036-1579757 · DOI
  5. Rebelo, 2021, Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: Not a needle in a haystack, Endocr. Connect., 10, R293, 10.1530/EC-21-0294 · DOI
  6. Clark, 2009, The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy, Kidney Int., 76, 939, 10.1038/ki.2009.296 · DOI
  7. Ohh, 2022, Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata, eLife, 11, e80774, 10.7554/eLife.80774 · DOI
  8. Haase, 2006, The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease, Kidney Int., 69, 1302, 10.1038/sj.ki.5000221 · DOI · Paper page
  9. Tamura, 2023, Variant spectrum of von Hippel-Lindau disease and its genomic heterogeneity in Japan, Hum. Mol. Genet., 32, 2046, 10.1093/hmg/ddad039 · DOI · Paper page
  10. Horton, 2022, Universal Germline Panel Testing for Individuals with Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield, J. Clin. Endocrinol. Metab., 107, e1917, 10.1210/clinem/dgac014 · DOI
  11. Oldfield, 2022, VHL mosaicism: The added value of multi-tissue analysis, NPJ Genom. Med., 7, 21, 10.1038/s41525-022-00291-3 · doi:10.1038/s41525-022-00291-3
  12. Varshney, 2017, A Review of Von Hippel-Lindau Syndrome, J. Kidney Cancer VHL, 4, 20, 10.15586/jkcvhl.2017.88 · DOI · Paper page
  13. Choyke, 1995, von Hippel-Lindau disease: Genetic, clinical, and imaging features, Radiology, 194, 629, 10.1148/radiology.194.3.7862955 · DOI · Paper page
  14. Melmon, 1964, Lindau’s Disease. Review of the Literature and Study of a Large Kindred, Am. J. Med., 36, 595, 10.1016/0002-9343(64)90107-X · doi:10.1016/0002-9343(64)90107-x
  15. Seizinger, 1988, Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma, Nature, 332, 268, 10.1038/332268a0 · DOI · Paper page
  16. Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat. Rev. Cancer, 15, 55, 10.1038/nrc3844 · DOI · Paper page
  17. Tanimoto, 2000, Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein, EMBO J., 19, 4298, 10.1093/emboj/19.16.4298 · DOI · Paper page
  18. Richards, 1996, Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis, Hum. Mol. Genet., 5, 639, 10.1093/hmg/5.5.639 · DOI
  19. Knudson, 1971, Mutation and cancer: Statistical study of retinoblastoma, Proc. Natl. Acad. Sci. USA, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
  20. Glasker, 2001, Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system, J. Neurol. Neurosurg. Psychiatry, 70, 644, 10.1136/jnnp.70.5.644 · DOI
  21. Glasker, 2006, Second hit deletion size in von Hippel-Lindau disease, Ann. Neurol., 59, 105, 10.1002/ana.20704 · doi:10.1002/ana.20704
  22. Maddock, 1996, A genetic register for von Hippel-Lindau disease, J. Med. Genet., 33, 120, 10.1136/jmg.33.2.120 · DOI · Paper page
  23. Evans, 2010, Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service, Am. J. Med. Genet. A, 152A, 327, 10.1002/ajmg.a.33139 · DOI · Paper page
  24. Maher, 1991, Von Hippel-Lindau disease: A genetic study, J. Med. Genet., 28, 443, 10.1136/jmg.28.7.443 · DOI · Paper page
  25. Neumann, 1991, Clustering of features of von Hippel-Lindau syndrome: Evidence for a complex genetic locus, Lancet, 337, 1052, 10.1016/0140-6736(91)91705-Y · DOI · Paper page
  26. Binderup, 2017, Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark, Eur. J. Hum. Genet., 25, 301, 10.1038/ejhg.2016.173 · DOI
  27. Haase, 2005, The VHL tumor suppressor in development and disease: Functional studies in mice by conditional gene targeting, Semin. Cell Dev. Biol., 16, 564, 10.1016/j.semcdb.2005.03.006 · DOI
  28. Iliopoulos, 1996, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein, Proc. Natl. Acad. Sci. USA, 93, 10595, 10.1073/pnas.93.20.10595 · DOI · Paper page
  29. Tian, 2023, PI3K/AKT signaling activates HIF1alpha to modulate the biological effects of invasive breast cancer with microcalcification, NPJ Breast Cancer, 9, 93, 10.1038/s41523-023-00598-z · DOI
  30. Bae, 2024, Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer, Exp. Mol. Med., 56, 501, 10.1038/s12276-024-01180-8 · DOI · Paper page
  31. Chen, C.Y., Chen, J., He, L., and Stiles, B.L. (2018). PTEN: Tumor Suppressor and Metabolic Regulator. Front. Endocrinol., 9. · DOI · Paper page
  32. Singh, 2002, p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas, Genes. Dev., 16, 984, 10.1101/gad.973602 · DOI · Paper page
  33. Farhan, 2017, FOXO Signaling Pathways as Therapeutic Targets in Cancer, Int. J. Biol. Sci., 13, 815, 10.7150/ijbs.20052 · DOI · Paper page
  34. Vortmeyer, 2013, Nervous system involvement in von Hippel-Lindau disease: Pathology and mechanisms, Acta Neuropathol., 125, 333, 10.1007/s00401-013-1091-z · DOI
  35. Albanyan, 2019, Characterization of VHL promoter variants in patients suspected of Von Hippel-Lindau disease, Eur. J. Med. Genet., 62, 177, 10.1016/j.ejmg.2018.07.006 · DOI
  36. Hsieh, 2018, Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma, J. Clin. Oncol., 36, 3533, 10.1200/JCO.2018.79.2549 · DOI · Paper page
  37. Liu, Z., Zhou, J., Li, L., Yi, Z., Lu, R., Li, C., and Gong, K. (2020). Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippel-Lindau disease: Case report. BMC Med. Genet., 21. · DOI
  38. Peng, S., Zhang, J., Tan, X., Huang, Y., Xu, J., Silk, N., Zhang, D., Liu, Q., and Jiang, J. (2020). The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Front. Endocrinol., 11. · DOI
  39. Tarade, 2020, The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF, Protein Sci., 29, 1843, 10.1002/pro.3898 · DOI
  40. Buffet, 2020, Germline mutations in the new E1’ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma, J. Med. Genet., 57, 752, 10.1136/jmedgenet-2019-106519 · DOI
  41. Xie, 2020, Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: A large retrospective study, J. Med. Genet., 57, 744, 10.1136/jmedgenet-2019-106336 · DOI
  42. Reich, 2021, Genotype-phenotype correlation in von Hippel-Lindau disease, Acta Ophthalmol., 99, e1492, 10.1111/aos.14843 · doi:10.1111/aos.14843
  43. Sluiter, 2019, The incidence of consecutive manifestations in Von Hippel-Lindau disease, Fam. Cancer, 18, 369, 10.1007/s10689-019-00131-x · DOI
  44. Vocke, 2021, Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families, Hum. Mutat., 42, 520, 10.1002/humu.24194 · doi:10.1002/humu.24194
  45. Cybulski, 2002, Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: Disease presentation in patients with deletions of the entire VHL gene, J. Med. Genet., 39, E38, 10.1136/jmg.39.7.e38 · DOI
  46. Tabaro, F., Minervini, G., Sundus, F., Quaglia, F., Leonardi, E., Piovesan, D., and Tosatto, S.C. (2016). VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Sci. Rep., 6. · DOI
  47. Ong, 2007, Genotype-phenotype correlations in von Hippel-Lindau disease, Hum. Mutat., 28, 143, 10.1002/humu.20385 · DOI · Paper page
  48. Zbar, 1996, Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan, Hum. Mutat., 8, 348, 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3 · DOI · Paper page
  49. Chen, 1995, Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype, Hum. Mutat., 5, 66, 10.1002/humu.1380050109 · DOI · Paper page
  50. Kanno, 1996, Molecular genetic diagnosis of von Hippel-Lindau disease: Analysis of five Japanese families, Jpn. J. Cancer Res., 87, 423, 10.1111/j.1349-7006.1996.tb00240.x · doi:10.1111/j.1349-7006.1996.tb00240.x
  51. Moore, 2000, Identification of a novel mutation (c279delC) and a polymorphism (c291C>G) in the von Hippel-Lindau gene in Italian patients, Hum. Mutat., 15, 582, 10.1002/1098-1004(200006)15:6<582::AID-HUMU18>3.0.CO;2-P · doi:10.1002/1098-1004(200006)15:6<582::aid-humu18>3.0.co;2-p
  52. Crossey, 1994, Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype, Hum. Mol. Genet., 3, 1303, 10.1093/hmg/3.8.1303 · DOI · Paper page
  53. Stolle, 1998, Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene, Hum. Mutat., 12, 417, 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K · DOI · Paper page
  54. Rechsteiner, 2011, VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: Identification of potential driver and passenger mutations, Cancer Res., 71, 5500, 10.1158/0008-5472.CAN-11-0757 · DOI · Paper page
  55. Bravo, 2004, Genetic characterization and structural analysis of VHL Spanish families to define genotype-phenotype correlations, Hum. Mutat., 23, 160, 10.1002/humu.10309 · DOI
  56. Webster, 1999, Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation, Arch. Ophthalmol., 117, 371, 10.1001/archopht.117.3.371 · doi:10.1001/archopht.117.3.371
  57. van Houwelingen, K.P., van Dijk, B.A., Hulsbergen-van de Kaa, C.A., Schouten, L.J., Gorissen, H.J., Schalken, J.A., van den Brandt, P.A., and Oosterwijk, E. (2005). Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: Results from The Netherlands cohort study. BMC Cancer, 5. · DOI
  58. Rocha, 2003, High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil, J. Med. Genet., 40, e31, 10.1136/jmg.40.3.e31 · DOI
  59. Lolkema, 2010, Genetic analysis of von Hippel-Lindau disease, Hum. Mutat., 31, 521
  60. Cho, 2009, Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis, J. Korean Med. Sci., 24, 77, 10.3346/jkms.2009.24.1.77 · DOI
  61. Wu, 2012, Family history of von Hippel-Lindau disease was uncommon in Chinese patients: Suggesting the higher frequency of de novo mutations in VHL gene in these patients, J. Hum. Genet., 57, 238, 10.1038/jhg.2012.10 · DOI
  62. Kang, 2005, Three novel VHL germline mutations in Korean patients with von Hippel-Lindau disease and pheochromocytomas, Oncol. Rep., 14, 879
  63. Clinical Research Group for VHL in Japan (1995). Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Hum. Mol. Genet., 4, 2233–2237. · doi:10.1093/hmg/4.12.2233
  64. Neumann, 2002, Germ-line mutations in nonsyndromic pheochromocytoma, N. Engl. J. Med., 346, 1459, 10.1056/NEJMoa020152 · DOI · Paper page
  65. Yoshida, 2000, Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: An extended study of 77 families, Jpn. J. Cancer Res., 91, 204, 10.1111/j.1349-7006.2000.tb00933.x · DOI
  66. Olschwang, 1998, Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma, Hum. Mutat., 12, 424, 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H · DOI · Paper page
  67. Glavac, 1996, Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe, Hum. Genet., 98, 271, 10.1007/s004390050206 · DOI
  68. Maher, 1996, Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations, J. Med. Genet., 33, 328, 10.1136/jmg.33.4.328 · DOI · Paper page
  69. Vortmeyer, 1997, Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas, Am. J. Pathol., 151, 951
  70. Bauters, 2003, Hereditary phaeochromocytomas and paragangliomas: A study of five susceptibility genes, J. Med. Genet., 40, e75, 10.1136/jmg.40.6.e75 · DOI
  71. Ritter, 1996, Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease, J. Clin. Endocrinol. Metab., 81, 1035
  72. Hes, 2007, Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification, Clin. Genet., 72, 122, 10.1111/j.1399-0004.2007.00827.x · DOI
  73. Wang, 2014, Higher prevalence of novel mutations in VHL gene in Chinese Von Hippel-Lindau disease patients, Urology, 83, 675.e1, 10.1016/j.urology.2013.09.069 · DOI
  74. Garcia, 1997, Molecular diagnosis of von Hippel-Lindau disease in a kindred with a predominance of familial phaeochromocytoma, Clin. Endocrinol., 46, 359, 10.1046/j.1365-2265.1997.00149.x · doi:10.1046/j.1365-2265.1997.00149.x
  75. Lee, J.S., Lee, J.H., Lee, K.E., Kim, J.H., Hong, J.M., Ra, E.K., Seo, S.H., Lee, S.J., Kim, M.J., and Park, S.S. (2016). Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-alpha binding site missense mutations elevate age-specific risk for CNS hemangioblastoma. BMC Med. Genet., 17. · DOI
  76. Crossey, 1995, Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma, J. Med. Genet., 32, 885, 10.1136/jmg.32.11.885 · DOI · Paper page
  77. Gross, 1996, Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene, J. Clin. Endocrinol. Metab., 81, 147
  78. Bar, 1997, Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes, Clin. Endocrinol., 47, 707, 10.1046/j.1365-2265.1997.3251150.x · DOI · Paper page
  79. Tisherman, 1962, Familial pheochromocytoma, JAMA, 182, 152, 10.1001/jama.1962.03050410048010 · doi:10.1001/jama.1962.03050410048010
  80. Murgia, 2000, Somatic mosaicism in von Hippel-Lindau Disease, Hum. Mutat., 15, 114, 10.1002/(SICI)1098-1004(200001)15:1<114::AID-HUMU20>3.0.CO;2-7 · DOI
  81. Mete, 2014, Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family, Endocrine, 45, 128, 10.1007/s12020-013-9982-2 · doi:10.1007/s12020-013-9982-2
  82. Atuk, 1998, Pheochromocytoma in von Hippel-Lindau disease: Clinical presentation and mutation analysis in a large, multigenerational kindred, J. Clin. Endocrinol. Metab., 83, 117
  83. Brookes, 2013, Diagnostic genetics at a distance: Von hippel-lindau disease and a novel mutation, Genet. Res. Int., 2013, 189196
  84. Ganeshan, 2018, Tumors in von Hippel-Lindau Syndrome: From Head to Toe-Comprehensive State-of-the-Art Review, Radiographics, 38, 849, 10.1148/rg.2018170156 · DOI
  85. Chittiboina, 2015, Von Hippel-Lindau disease, Handb. Clin. Neurol., 132, 139, 10.1016/B978-0-444-62702-5.00010-X · DOI · Paper page
  86. Qiu, J., Zhang, K., Ma, K., Zhou, J., Gong, Y., Cai, L., and Gong, K. (2020). The Genotype-Phenotype Association of Von Hipple Lindau Disease Based on Mutation Locations: A Retrospective Study of 577 Cases in a Chinese Population. Front. Genet., 11. · DOI
  87. Stebbins, 1999, Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function, Science, 284, 455, 10.1126/science.284.5413.455 · DOI · Paper page
  88. Domene, 2012, Effects of point mutations in pVHL on the binding of HIF-1alpha, Proteins, 80, 733, 10.1002/prot.23230 · DOI
  89. Razafinjatovo, C., Bihr, S., Mischo, A., Vogl, U., Schmidinger, M., Moch, H., and Schraml, P. (2016). Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: Hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer, 16. · DOI
  90. Zhou, 2004, Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent, Cancer Res., 64, 1278, 10.1158/0008-5472.CAN-03-0884 · DOI · Paper page
  91. Cervio, 2017, Surgical treatment of cerebellar hemangioblastomas, Surg. Neurol. Int., 8, 163, 10.4103/sni.sni_490_16 · doi:10.4103/sni.sni_490_16
  92. Klingler, 2020, Hemangioblastoma and von Hippel-Lindau disease: Genetic background, spectrum of disease, and neurosurgical treatment, Childs Nerv. Syst., 36, 2537, 10.1007/s00381-020-04712-5 · doi:10.1007/s00381-020-04712-5
  93. Karimi, 2020, Von Hippel-Lindau Disease and the Eye, J. Ophthalmic Vis. Res., 15, 78
  94. Singh, 2001, von Hippel-Lindau disease, Surv. Ophthalmol., 46, 117, 10.1016/S0039-6257(01)00245-4 · DOI · Paper page
  95. Lin, 2020, Clinical diagnosis, treatment and screening of the VHL gene in three von Hippel-Lindau disease pedigrees, Exp. Ther. Med., 20, 1237, 10.3892/etm.2020.8829 · DOI
  96. Jabi, 2014, Subclinical Pheochromocytoma and Paraganglioma in an Elderly Patient: A Case Report, JSM Clin. Rep., 2, 1036
  97. Brouwers, 2013, Pancreatic cyst development: Insights from von Hippel-Lindau disease, Cilia, 2, 3, 10.1186/2046-2530-2-3 · DOI
  98. Blansfield, 2007, Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs), Surgery, 142, 814, 10.1016/j.surg.2007.09.012 · doi:10.1016/j.surg.2007.09.012
  99. Maher, 2011, von Hippel-Lindau disease: A clinical and scientific review, Eur. J. Hum. Genet., 19, 617, 10.1038/ejhg.2010.175 · DOI · Paper page
  100. Zanoletti, 2017, Endolymphatic sac tumour in von Hippel-Lindau disease: Management strategies, Acta Otorhinolaryngol. Ital., 37, 423, 10.14639/0392-100X-1402 · doi:10.14639/0392-100x-1402
  101. Butman, 2007, Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease, JAMA, 298, 41, 10.1001/jama.298.1.41 · DOI
  102. Gomella, 2019, Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau, Urol. Case Rep., 27, 100922, 10.1016/j.eucr.2019.100922 · doi:10.1016/j.eucr.2019.100922
  103. Papadakis, 2016, Epididymal Cystadenomas in von Hippel-Lindau Disease Showing Increased Activity on 68Ga DOTATATE PET/CT, Clin. Nucl. Med., 41, 781, 10.1097/RLU.0000000000001314 · DOI
  104. Oliveira, 2020, Tumors of the broad ligament: What and when to suspect such rare location, Radiol. Bras., 53, 349, 10.1590/0100-3984.2019.0073 · doi:10.1590/0100-3984.2019.0073
  105. Nogales, 2012, An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: Four associated with von Hippel-Lindau disease and one aggressive sporadic type, Histopathology, 60, 748, 10.1111/j.1365-2559.2011.04151.x · doi:10.1111/j.1365-2559.2011.04151.x
  106. McDonough, 2006, Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2), Proc. Natl. Acad. Sci. USA, 103, 9814, 10.1073/pnas.0601283103 · DOI · Paper page
  107. Robb, 2007, Activation of the mTOR signaling pathway in renal clear cell carcinoma, J. Urol., 177, 346, 10.1016/j.juro.2006.08.076 · DOI · Paper page
  108. Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016 · DOI · Paper page
  109. Zoncu, 2011, mTOR: From growth signal integration to cancer, diabetes and ageing, Nat. Rev. Mol. Cell Biol., 12, 21, 10.1038/nrm3025 · DOI · Paper page
  110. Gingras, 2001, Regulation of translation initiation by FRAP/mTOR, Genes. Dev., 15, 807, 10.1101/gad.887201 · DOI · Paper page
  111. Porta, C., Paglino, C., and Mosca, A. (2014). Targeting PI3K/Akt/mTOR Signaling in Cancer. Front. Oncol., 4. · DOI · Paper page
  112. Kucejova, 2011, Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma, Mol. Cancer Res., 9, 1255, 10.1158/1541-7786.MCR-11-0302 · DOI
  113. Doan, 2019, HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer, iScience, 21, 509, 10.1016/j.isci.2019.10.047 · DOI
  114. Ganner, A., Gehrke, C., Klein, M., Thegtmeier, L., Matulenski, T., Wingendorf, L., Wang, L., Pilz, F., Greidl, L., and Meid, L. (2021). VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci. Rep., 11. · DOI
  115. Rini, 2008, Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma, Urol. Oncol., 26, 543, 10.1016/j.urolonc.2008.03.012 · DOI
  116. Rini, 2009, Resistance to targeted therapy in renal-cell carcinoma, Lancet Oncol., 10, 992, 10.1016/S1470-2045(09)70240-2 · DOI · Paper page
  117. Bellmunt, 2014, Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: Efficacy and toxicity, Clin. Genitourin. Cancer, 12, 262, 10.1016/j.clgc.2014.03.002 · DOI
  118. Yao, 2017, VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma, Cancer Discov., 7, 1284, 10.1158/2159-8290.CD-17-0375 · DOI · Paper page
  119. Zhang, 2018, VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma, Science, 361, 290, 10.1126/science.aap8411 · DOI · Paper page
  120. Zhu, 2020, ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma, Cell Death Dis., 11, 337, 10.1038/s41419-020-2541-x · DOI
  121. Liu, 2020, Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss, Mol. Cell, 77, 1294, 10.1016/j.molcel.2020.01.009 · DOI
  122. Chen, 2021, Novel VHL substrate targets SFMBT1 and ZHX2 may be important prognostic predictors in patients with ccRCC, Oncol. Lett., 21, 379, 10.3892/ol.2021.12640 · DOI
  123. Tedesco, 2019, von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME, Cell Death Dis., 10, 266, 10.1038/s41419-019-1507-3 · DOI
  124. Hu, 2020, TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss, Cancer Discov., 10, 460, 10.1158/2159-8290.CD-19-0837 · DOI · Paper page
  125. Kanno, 2020, Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease, J. Neurooncol., 148, 29, 10.1007/s11060-020-03506-8 · DOI
  126. Perrotta, 2006, Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: Identification of a novel cluster, Blood, 107, 514, 10.1182/blood-2005-06-2422 · DOI · Paper page
  127. Bento, 2005, Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: Five new Caucasian patients, Haematologica, 90, 128
  128. Gnarra, 1997, Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice, Proc. Natl. Acad. Sci. USA, 94, 9102, 10.1073/pnas.94.17.9102 · DOI · Paper page
  129. Voest, 2010, von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish, Dis. Model. Mech., 3, 343, 10.1242/dmm.004036 · DOI
  130. Chew, 2005, Ocular manifestations of von Hippel-Lindau disease: Clinical and genetic investigations, Trans. Am. Ophthalmol. Soc., 103, 495
  131. Rankin, 2006, Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor, Cancer Res., 66, 2576, 10.1158/0008-5472.CAN-05-3241 · DOI · Paper page
  132. Ding, 2006, Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice, Nat. Med., 12, 1081, 10.1038/nm1460 · DOI · Paper page
  133. Shen, H.C., Adem, A., Ylaya, K., Wilson, A., He, M., Lorang, D., Hewitt, S.M., Pechhold, K., Harlan, D.M., and Lubensky, I.A. (2009). Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS ONE, 4. · DOI
  134. Frew, 2008, Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia, Mol. Cell Biol., 28, 4536, 10.1128/MCB.02132-07 · DOI
  135. Hong, 2006, Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis, Lab. Investig., 86, 664, 10.1038/labinvest.3700431 · DOI
  136. Haase, 2001, Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor, Proc. Natl. Acad. Sci. USA, 98, 1583, 10.1073/pnas.98.4.1583 · DOI · Paper page
  137. Ma, 2003, Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene, Cancer Res., 63, 5320
  138. Park, 2012, Von Hippel-Lindau disease (VHL): A need for a murine model with retinal hemangioblastoma, Histol. Histopathol., 27, 975
  139. Patard, 2009, Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma, Br. J. Cancer, 101, 1417, 10.1038/sj.bjc.6605298 · DOI · Paper page
  140. Los, 1997, Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease, Ann. Oncol., 8, 1015, 10.1023/A:1008213320642 · DOI
  141. 2017, Prognostic Value of the VHL, HIF-1alpha, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study, Clin. Genitourin. Cancer, 15, e923, 10.1016/j.clgc.2017.05.016 · DOI
  142. NIH/FDA (2024, August 22). BEST (Biomarkers, EndpointS, and Other Tools) Resource, Available online: https://www.ncbi.nlm.nih.gov/books/NBK326791/.
  143. Wang, 2017, Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients, Cancer Med., 6, 2131, 10.1002/cam4.1134 · DOI
  144. Maroto, 2017, HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma, OncoTargets Ther., 10, 4635, 10.2147/OTT.S137677 · DOI
  145. Qi, 2018, SERPINH1 overexpression in clear cell renal cell carcinoma: Association with poor clinical outcome and its potential as a novel prognostic marker, J. Cell. Mol. Med., 22, 1224, 10.1111/jcmm.13495 · DOI
  146. Hong, 2019, Differential Expression of PD-L1 between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation with Clinicopathological Features, Clin. Genitourin. Cancer, 17, 97, 10.1016/j.clgc.2018.11.001 · DOI
  147. Radspieler, 2019, Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma, Oncol. Lett., 18, 2654
  148. Zhang, 2020, Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma, Cancer Cell Int., 20, 584, 10.1186/s12935-020-01670-5 · DOI
  149. Yang, 2021, Identification and validation of the clinical roles of the VHL-related LncRNAs in clear cell renal cell carcinoma, J. Cancer, 12, 2702, 10.7150/jca.55113 · DOI
  150. Oosting, 2016, 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease, J. Nucl. Med., 57, 1244, 10.2967/jnumed.115.167643 · doi:10.2967/jnumed.115.167643
  151. Shell, 2019, The utility of (68)Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors, Eur. J. Radiol., 112, 130, 10.1016/j.ejrad.2018.11.023 · doi:10.1016/j.ejrad.2018.11.023
  152. Xiao, 2021, The prevalence, genetic complexity and population-specific founder effects of human autosomal recessive disorders, NPJ Genom. Med., 6, 41, 10.1038/s41525-021-00203-x · DOI
  153. McCarthy, 2008, Genome-wide association studies for complex traits: Consensus, uncertainty and challenges, Nat. Rev. Genet., 9, 356, 10.1038/nrg2344 · DOI · Paper page
  154. Mbemi, A., Khanna, S., Njiki, S., Yedjou, C.G., and Tchounwou, P.B. (2020). Impact of Gene-Environment Interactions on Cancer Development. Int. J. Environ. Res. Public Health, 17. · DOI
  155. Marmot, 2008, Commission on Social Determinants of H. Closing the gap in a generation: Health equity through action on the social determinants of health, Lancet, 372, 1661, 10.1016/S0140-6736(08)61690-6 · DOI · Paper page
  156. Knickelbein, 2017, Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease, Ophthalmol. Retina, 1, 181, 10.1016/j.oret.2016.10.007 · DOI
  157. Jonasch, 2011, Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease, Ann. Oncol., 22, 2661, 10.1093/annonc/mdr011 · DOI
  158. Hwang, 2021, Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab, and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial, Clin. Exp. Ophthalmol., 49, 1048, 10.1111/ceo.14001 · DOI
  159. Batist, 2002, Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels, Ann. Oncol., 13, 1259, 10.1093/annonc/mdf195 · doi:10.1093/annonc/mdf195
  160. Escudier, 2007, Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941, J. Urol., 178, 1901, 10.1016/j.juro.2007.07.035 · DOI
  161. Aguirre, 2019, Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: Phase III clinical trial, BMJ Open Ophthalmol., 4, e000203, 10.1136/bmjophth-2018-000203 · DOI
  162. Panakis, 2008, Sorafenib therapy and CNS hemangioblastomas in individuals with Von Hippel Lindau syndrome, J. Clin. Oncol., 26, 2065, 10.1200/jco.2008.26.15_suppl.2065 · doi:10.1200/jco.2008.26.15_suppl.2065
  163. Jonasch, 2018, Pazopanib in patients with von Hippel-Lindau disease: A single-arm, single-centre, phase 2 trial, Lancet Oncol., 19, 1351, 10.1016/S1470-2045(18)30487-X · DOI · Paper page
  164. Hasanov, 2021, MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma, Expert. Opin. Investig. Drugs, 30, 495, 10.1080/13543784.2021.1925248 · DOI
  165. Pilie, 2016, Pilot study of dovitinib in patients with VHL disease, J. Clin. Oncol., 34, 587, 10.1200/jco.2016.34.2_suppl.587 · doi:10.1200/jco.2016.34.2_suppl.587
  166. Wong, 2008, Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease, Ophthalmology, 115, 1957, 10.1016/j.ophtha.2008.04.033 · DOI
  167. Stamatakis, 2013, Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma, J. Clin. Oncol., 31, 4584, 10.1200/jco.2013.31.15_suppl.4584 · doi:10.1200/jco.2013.31.15_suppl.4584
  168. Ma, K., Hong, B., Zhou, J., Gong, Y., Wang, J., Liu, S., Peng, X., Zhou, B., Zhang, J., and Xie, H. (2019). The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients. Front. Oncol., 9. · DOI
  169. Friedrich, 1999, Von Hippel-Lindau syndrome. A pleomorphic condition, Cancer, 86, 2478, 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5 · DOI · Paper page
  170. Nagai, 2000, Plasma levels of vascular endothelial growth factor in patients with acromegaly, Horm. Metab. Res., 32, 326, 10.1055/s-2007-978645 · DOI
  171. Schraml, 2002, VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma, J. Pathol., 196, 186, 10.1002/path.1034 · DOI · Paper page

Cited by

See all 18

Metadata

Authors
Gómez-Virgilio, L., Velazquez-Paniagua, M., Cuazozon-Ferrer, L., Silva-Lucero, M.-D.-C., Gutierrez-Malacara, A.-I., Padilla-Mendoza, J.-R., Borbolla-Vázquez, J., Díaz-Hernández, J.-A., Jiménez-Orozco, F.-A., & Cardenas-Aguayo, M.-D.-C.
Venue
Diagnostics
Publisher
MDPI AG
Published
2024-08-29
Volume
14
Issue
17
Pages
1909
ISSN
2075-4418
Cited by
18
References
14
Language
en
Funders
CONAHCYT, “Ciencia Básica, Ciencia de Frontera Modalidad: Paradigmas y Controversias de la Ciencia 2022” (319578)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.